ReviewInternational journal of molecular sciences2023
Vitiligo: Pathogenesis and New and Emerging Treatments.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Janus microneedles enabling orderly vitiligo treatment through spatiotemporal sequential promoting melanogenesis to transferAsian journal of pharmaceutical sciences · 2026Article
- Cold atmospheric plasma (CAP) stimulates melanoblast-to-melanocyte differentiation via PRKCQ upregulation and NF-κB activation.iScience · 2026Article
- The Role of Phytocompounds and the Physiological Response of the Skin in Common Dermatological Conditions: A Narrative Review and Bibliometric Analysis of Trends.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- Bidirectional Mendelian Randomization Suggests Causal Effects of 731 Immunophenotypes on Vitiligo Pathogenesis.Clinical, cosmetic and investigational dermatology · 2026Article
- Exploring the Role of Radix Polygalae in Melanogenesis Related to Vitiligo: A Network Pharmacology Analysis with in vitro Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- Investigating the Gut Microbiota-Inflammatory Cytokine-Skin Axis in Inflammatory Skin Diseases: Evidence from Mendelian Randomization.Clinical, cosmetic and investigational dermatology · 2026Article
- Effectiveness of 308-nm Excimer Light with Pimecrolimus and Crisaborole in Pediatric Vitiligo: A Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma - Multifaceted Control.Clinical, cosmetic and investigational dermatology · 2026Article
- Understanding vitiligo-related concerns through online discourse: an AI-assisted cross-platform study of Chinese and global communities.Frontiers in public health · 2026Article
- JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential.Drugs · 2025Review
- Expanding Horizons: Next-Generation and Interdisciplinary Advances in the Applications of Extracellular Vesicles.Journal of extracellular biology · 2025Review
- recent advances in the pathogenesis of vitiligo and the application of novel drug delivery systems in its treatment.International journal of pharmaceutics: X · 2025Review
- Article
- Impact of Vitiligo on Major Life-changing Decisions and Perceived Stigmatization: A Cross-sectional Study.Acta dermato-venereologica · 2025Observational
- Canadian Consensus Guidelines for the Management of Vitiligo.Dermatology and therapy · 2025Article
- Vogt-Koyanagi-Harada disease in a patient with retinitis pigmentosa in one eye and pigmented paravenous retinochoroidal atrophy in the other eye.American journal of ophthalmology case reports · 2025Article
- Review
- Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a complex disease with a multifactorial nature and a high impact on the quality of life of patients. Although there are multiple therapeutic alternatives, there is currently no fully effective treatment for this disease. In the current era, multiple drugs are being developed for the treatment of autoimmune diseases. This review assesses the available evidence on the pathogenesis of vitiligo, and a comprehensive review of treatments available for vitiligo now and in the near future is provided. This qualitative analysis spans 116 articles. We reviewed the mechanism of action, efficacy and safety data of phototherapy, afamelanotide, cyclosporine, phosphodiesterase 4 inhibitors, trichloroacetic acid, basic fibroblast growth factor, tumor necrosis factor (TNF) inhibitors, secukinumab, pseudocatalase and janus kinase (JAK) inhibitors. At the moment, there is no clearly outstanding option or fully satisfactory treatment for vitiligo, so it is necessary to keep up the development of new drugs as well as the publication of long-term effectiveness and safety data for existing treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.